Associations of GSTM1*0 and GSTA1*Agenotypes with the risk of cardiovascular death among hemodialyses patients

Table 2 GSTM1 polymorphism as a predictor for overall and cardiovascular mortality as well as death of myocardial infarction and cerebral vascular insult among 199 ESRD patients after a median follow-up time of 8 yrs by Cox proportional hazards regression models

Model 1^a		Model 2^b		Model 3^c
HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Risk for overall mortality comparing *GSTM1-null* homozygotes to *GSTM1-active* carriers
1.74 (0.96-3.14)	0.066	1.88 (1.03-3.45)	0.041	2.08 (1.10-3.92)	0.024
Risk for cardiovascular mortality comparing *GSTM1-null* homozygotes to *GSTM- active* carriers
1.96 (0.95-4.08)	0.070	2.03 (0.97-4.22)	0.060	2.19 (1.01-4.79)	0.050
Risk for death from myocardial infarction comparing *GSTM1-null* homozygotes to *GSTM1-active* carriers
1.70 (0.65-4.49)	0.281	1.74 (0.66-4.60)	0.263	1.82 (0.63-5.26)	0.270
Risk for death from CVI comparing *GSTM1-null* homozygotes to *GSTM1-active* carriers
3.38 (0.96-11.94)	0.058	3.54 (0.99-12.56)	0.051	3.80 (1.03-14.02)	0.045

Abbreviations: CI Confidence Interval, HR Hazard Ratio.
^aAdjusted for age and gender.
^bAdjusted for the covariates in Model 1 plus an additional adjustment for smoking status.
^cAdjusted for the covariates in Model 2 plus an additional adjustment for diabetes and cholesterol level.

ISSN: 1471-2369